Clinigen Group (OTCMKTS:CLIGF) Downgraded by Zacks Investment Research to Sell

Zacks Investment Research downgraded shares of Clinigen Group (OTCMKTS:CLIGF) from a hold rating to a sell rating in a research note published on Wednesday, Zacks.com reports.

According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

Shares of OTCMKTS CLIGF opened at $12.90 on Wednesday. The firm’s fifty day moving average price is $12.90. Clinigen Group has a twelve month low of $9.87 and a twelve month high of $12.90.



Recommended Story: Quiet Period

Get a free copy of the Zacks research report on Clinigen Group (CLIGF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.